The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60 years-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60 years

Published:2017-11 Issue:6 Volume:31 Page:362-369
ISSN:0268-960X
Container-title:Blood Reviews
language:en
Short-container-title:Blood Reviews

Author:

Wall Sarah A.,Devine Steven^ORCID,Vasu Sumithira

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference67 articles.

1. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60years: results from AMLSG trial AML HD98-B;Frohling;Blood,2006

2. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461;Farag;Blood,2006

3. Age and acute myeloid leukemia;Appelbaum;Blood,2006

4. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents;Barrett;Leukemia,2006

5. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies;Sorror;JAMA,2011

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health professionals’ perceptions of prehabilitation before haematopoietic cell transplantation to optimise candidacy in older adults;Supportive Care in Cancer;2024-06-26

2. Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity;Nature Cancer;2024-02-27

3. Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure;Blood Cancer Journal;2023-12-10

4. Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress;Expert Review of Anticancer Therapy;2023-07-20

5. Lower intensity regimens for acute myeloid leukemia: opportunities and challenges;Leukemia & Lymphoma;2022-11-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3